4,6-dimethyl-2-methoxy-1,3,2-dioxaphosphorinane | 95977-88-1

• 分子结构分类: 有机化合物 - 有机磷化合物 - 亚磷酸三烷基酯
• 英文名称: 4,6-dimethyl-2-methoxy-1,3,2-dioxaphosphorinane
• 英文别名: 2-methoxy-4r,6t-dimethyl-[1,3,2]dioxaphosphinane；(4R*,6R*)-2-Methoxy-4,6-dimethyl-[1,3,2]dioxaphosphinane；(4R,6R)-2-methoxy-4,6-dimethyl-1,3,2-dioxaphosphinane
• CAS: 95977-88-1
• 化学式: C₆H₁₃O₃P
• 分子量: 164.141
• InChiKey: GNWZQVMWSLTQMZ-PHDIDXHHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,6-dimethyl-2-methoxy-1,3,2-dioxaphosphorinane 在 sulfur 作用下， 以 苯 为溶剂， 反应 72.0h， 生成 4,6-dimethyl-2-oxo-1,3,2-dioxaphosphorinane-2-thione tetramethylammonium salt
  参考文献：
  名称：

  Mikolajczyk, Marian; Ziemnicka, Barbara; Wieczorek, Michal W., Phosphorus and Sulfur and the Related Elements, 1984, vol. 21, p. 205 - 214

  摘要：

  DOI：
• 作为产物：
  描述：

  (2R,4R)-pentanediol 、 三甲氧基磷 以51%的产率得到4,6-dimethyl-2-methoxy-1,3,2-dioxaphosphorinane
  参考文献：
  名称：

  Synthesis and Biological Activities of Optical Isomers of 2-(4-Diphenylmethl-1-piperazinly)ethyl 5-(4,6-Dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate Dihydrochloride(NIP-101).

  摘要：

  通过使用光学活性（2R，4R）-（-）-和（2S，4S）-（+）-2，4-戊二醇和顺式-2，4-戊二醇以及光学活性（S）-（+）-2-甲氧基-2-苯基乙醇，成功地制备了六种光学异构体，即2-(4-二苯甲基-1-哌嗪基)乙基5-(4，6-二甲基-2-氧代-1，3，2-二氧杂磷杂环己烷-2-基)-1，4-二氢-2，6-二甲基-4-(3-间苯基)-3-吡啶羧酸盐二盐酸盐（NIP-101，1·2HCl·2H2O），这是一种有效的钙拮抗剂。其质子核磁共振研究表明，1，3，2-二氧杂磷杂环己烷基团在构象上受C-P键的限制。对光学异构体的钙拮抗和降压活性进行了研究，发现它们主要取决于1，4-二氢吡啶环中立体中心处的绝对构型，而不是1，3，2-二氧杂磷杂环己烷基团的构型。

  DOI：

  10.1248/cpb.40.2370

文献信息

• Dihydropyridine-5-phosphonic acid cyclic ester
  申请人：NISSAN CHEMICAL INDUSTRIES LTD.

  公开号：EP0260605A2

  公开（公告）日：1988-03-23

  An optical isomer of a compound having the formula: wherein the two methyl groups at 4- and 6-positions of the dioxaphosphorinane ring assume trans configurations to each other, which has a levo-rotatory angle of optical rotation attributable to the asymmetric carbon atom at 4-position of the dihydropyridine ring, and a pharmaceutically acceptable salt thereof.

  一种具有以下式子的化合物的光学异构体 其中二氧磷环 4 位和 6 位上的两个甲基彼此呈反式构型，其光学旋转角度为二氢吡啶环 4 位上不对称碳原子的左旋角，以及其药学上可接受的盐。
• Oxygen-17 NMR spectra of cyclic phosphites, phosphates, and thiophosphates
  作者：Ernest L. Eliel、Subramanian. Chandrasekaran、Leslie E. Carpenter、John G. Verkade

  DOI：10.1021/ja00281a034

  日期：1986.10
• 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP2558474B1

  公开（公告）日：2015-11-25
• Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
  申请人：Singh Rajinder

  公开号：US20140357598A1

  公开（公告）日：2014-12-04

  The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
• METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20210283152A1

  公开（公告）日：2021-09-16

  Provided herein are a variety of methods that involve administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having or suspected of having a COVID-19 infection. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop acute respiratory distress syndrome, acute kidney injury, and/or thrombosis. In some embodiments, the method may comprise administering fostamatinib, an active component thereof or a pharmaceutically acceptable salt thereof to a patient having, suspected of having or expected to develop symptoms associated with a cytokine response. Aspects of the methods may further include identifying a patient with kidney malfunction, e.g., acute kidney injury, and/or thrombosis.